The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.

Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory ...

The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

Stocks traded higher Wednesday as Wall Street focused on the latest tariff developments from President Donald Trump and ...

U.S. drugmaker Merck is nearing a deal worth about $10 billion to buy Verona Pharma, a company focused on therapies for lung ...

Merck will buy UK-based Verona Pharma for about $10 billion, the companies said on Wednesday, strengthening the U.S. firm's ...

The New Jersey-based pharma has inked one of the biggest deals of the year in pursuit of a promising new way to treat COPD.

Verona Pharma plc (NASDAQ:VRNA) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds.

Merck said the deal is valued at $107 per ADS, a 23% premium to Verona’s closing price yesterday.

A Verona man accused of possessing child pornography pleaded guilty to several felonies in Augusta Circuit Court.

Merck is expanding its pipeline and portfolio of cardio-pulmonary disease treatments by acquiring Verona Pharma plc.

A Verona man accused of possessing child pornography pleaded guilty to several felonies in Augusta Circuit Court.